Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-138497 · Präparat HOS-098200
16
OESTROGEN-BASED CONTRACEPTIVES
Drospirenone Ethinylestradiol drospirenone AUC ↑ 58% Alternative or additional
(3 mg/0.02 mg once daily) drospirenone Cmax ↑ 15% contraceptive measures are
drospirenone Cmin ND recommended when oestrogen
based contraceptives are
Ethinylestradiol ethinylestradiol AUC 30% co-administered with Symtuza.
ethinylestradiol Cmax 14% Patients using oestrogens as
hormone replacement therapy
ethinylestradiol Cmin ND
should be clinically monitored for
signs of oestrogen deficiency.
Norethindrone When Symtuza is co-administered
Based on theoretical considerations
with a drospirenone-containing
DRV/COBI may alter
product, clinical monitoring is
norethindrone plasma
recommended due to the potential
concentrations.
for hyperkalaemia.
OPIOID ANTAGONIST
Naloxegol Not studied. Co-administration of Symtuza
and naloxegol is contraindicated.
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
For the treatment of erectile Based on theoretical considerations Concomitant use of PDE-5
dysfunction DRV/COBI is expected to increase inhibitors for the treatment of
Sildenafil these PDE-5 inhibitor plasma erectile dysfunction with Symtuza
Tadalafil concentrations. should be done with caution. If
Vardenafil (CYP3A inhibition) concomitant use of Symtuza with
sildenafil, vardenafil or tadalafil
is indicated, sildenafil at a single
dose not exceeding 25 mg in
48 hours, vardenafil at a single
dose not exceeding 2.5 mg in
72 hours or tadalafil at a single
dose not exceeding 10 mg in
72 hours is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) drospirenone (HOS-116422) naloxegol (HOS-109428) norethindrone (HOS-088136) sildenafil (HOS-086162) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage aa7062508756f1c87bf12ca07a66600fa31c5ce41ed8c3f995a573f111588667 · Zeichen 37362–40673 im Abschnitt
Wechselwirkungen · Tukysa
TUKYSA 50 mg film-coated tablets TUKYSA 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-145571 · Präparat HOS-099373
CYP3A substrates
Tucatinib is a strong CYP3A inhibitor. A clinical drug interaction study found that co-administration
of tucatinib with midazolam (a sensitive CYP3A substrate) resulted in an increase in midazolam
concentrations (3.0-fold Cmax (90% CI: 2.6, 3.4) and 5.7-fold AUC (90% CI: 5.0, 6.5)).
Co-administration of tucatinib with sensitive CYP3A substrates such as alfentanil, avanafil, buspirone,
darifenacin, darunavir, ebastine, everolimus, ibrutinib, lomitapide, lovastatin, midazolam, naloxegol,
saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir, triazolam, and vardenafil may increase their
systemic exposures which may increase the toxicity associated with a CYP3A substrate. Concomitant
use of tucatinib with CYP3A substrates, when minimal concentration changes may lead to serious or
life-threatening toxicities, should be avoided. If concomitant use is unavoidable, the CYP3A substrate
dosage should be decreased in accordance with the concomitant medicinal product SmPC.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) lovastatin (HOS-086157) lomitapide (HOS-086160) ebastine (HOS-132877) simvastatin (HOS-086158) avanafil (HOS-086161) naloxegol (HOS-109428) lead (HOS-085592) saquinavir (HOS-084522) tacrolimus (HOS-085202) darunavir (HOS-086181) everolimus (HOS-086310) buspirone (HOS-086325) sirolimus (HOS-085172) darifenacin (HOS-113065) triazolam (HOS-086168) tipranavir (HOS-086184) ibrutinib (HOS-086226) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T09:31:00Z · SHA-256 adbbdb974aceeb49def28fd6967671862f72abd36a9da5eedfd1b7260c9b3db3 · Passage 4b3fd5f017560760570faed906723a4854964f126b379e0e81d431b1065811bc · Zeichen 1850–2847 im Abschnitt
Wechselwirkungen · Retsevmo
Retsevmo 40 mg hard capsules Retsevmo 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-146815 · Präparat HOS-099572
Sensitive CYP3A4 substrates
Selpercatinib increased Cmax and AUC of midazolam (a CYP3A4 substrate) by approximately 39%
and 54%, respectively. Therefore, concomitant use with sensitive CYP3A4 substrates, (e.g., alfentanil,
avanafil, buspirone, conivaptan, darifenacin, darunavir, ebastine, lomitapide, lovastatin, midazolam,
naloxegol, nisoldipine, saquinavir, simvastatin, tipranavir, triazolam, vardenafil), should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) lovastatin (HOS-086157) lomitapide (HOS-086160) ebastine (HOS-132877) simvastatin (HOS-086158) conivaptan (HOS-128737) avanafil (HOS-086161) naloxegol (HOS-109428) saquinavir (HOS-084522) nisoldipine (HOS-114251) darunavir (HOS-086181) buspirone (HOS-086325) darifenacin (HOS-113065) triazolam (HOS-086168) tipranavir (HOS-086184) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage cfdd98013721cec7702691e58a399d79c90849bc3f50350904fe7bfe355bcc04 · Zeichen 2240–2668 im Abschnitt
Wechselwirkungen · Retsevmo
Retsevmo 40 mg film-coated tablets Retsevmo 80 mg film-coated tablets Retsevmo 120 mg film-coated tablets Retsevmo 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-146887 · Präparat HOS-099572
Sensitive CYP3A4 substrates
Selpercatinib increased Cmax and AUC of midazolam (a CYP3A4 substrate) by approximately 39%
and 54%, respectively. Therefore, concomitant use with sensitive CYP3A4 substrates, (e.g., alfentanil,
avanafil, buspirone, conivaptan, darifenacin, darunavir, ebastine, lomitapide, lovastatin, midazolam,
naloxegol, nisoldipine, saquinavir, simvastatin, tipranavir, triazolam, vardenafil), should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) lovastatin (HOS-086157) lomitapide (HOS-086160) ebastine (HOS-132877) simvastatin (HOS-086158) conivaptan (HOS-128737) avanafil (HOS-086161) naloxegol (HOS-109428) saquinavir (HOS-084522) nisoldipine (HOS-114251) darunavir (HOS-086181) buspirone (HOS-086325) darifenacin (HOS-113065) triazolam (HOS-086168) tipranavir (HOS-086184) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage cfdd98013721cec7702691e58a399d79c90849bc3f50350904fe7bfe355bcc04 · Zeichen 2184–2612 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.